Quest Diagnostics Expands Portfolio with Oxford Immunotec’s Cutting-Edge Tests
In a transformative move, Quest Diagnostics, a leading provider of diagnostic services, has acquired the U.S. laboratory services business of Oxford Immunotec, a pioneer in immune-regulated condition diagnostics. This strategic acquisition marks a significant milestone in the advancement of infectious disease testing, bringing together two industry leaders in the field.
T-SPOT.TB and Accutix: Innovative Tests for Tuberculosis and Tick-Borne Diseases
As part of the acquisition, Quest Diagnostics has incorporated Oxford Immunotec‘s T-SPOT.TB and Accutix tests into its portfolio of innovative infectious disease testing services. T-SPOT.TB is an interferon-gamma release assay (IGRA) that aids in the diagnosis of tuberculosis infection and disease, while Accutix provides accurate detection of tick-borne diseases. These tests enhance Quest Diagnostics’ ability to provide comprehensive and reliable testing solutions for a wide range of infectious diseases.
Long-Term Partnership for Continued Growth and Innovation
Beyond the acquisition, Oxford Immunotec and Quest Diagnostics have forged a strategic collaboration agreement to drive continued growth of T-SPOT.TB testing in the U.S. This partnership leverages the combined expertise of both companies to expand access to this critical test and improve patient outcomes.
Oxford Immunotec’s Continued Commitment to T-SPOT.TB Test Kit Supply
As part of the transaction, Oxford Immunotec will continue to manufacture and supply T-SPOT.TB test kits and related accessories to Quest Diagnostics under a long-term supply agreement. This ensures the uninterrupted availability of this essential test for healthcare providers and patients.
Quest Diagnostics’ Commitment to Physician Choice and Patient Care
Quest Diagnostics remains committed to providing physicians with a choice in blood-based TB testing. The company will continue to offer QuantiFERON TB testing services, allowing healthcare providers to select the most appropriate test for each patient based on their individual needs.
Blood-Based TB Testing: A Revolution in Diagnosis
Blood-based TB testing, including T-SPOT.TB, has revolutionized the diagnosis of tuberculosis. Traditional skin testing methods have limitations, including potential cross-reactivity and the need for multiple visits. In contrast, blood-based tests offer greater accuracy, convenience, and the ability to detect latent TB infection, which is crucial for preventing active disease.
Quest Diagnostics: Empowering Health Outcomes through Diagnostic Insights
Quest Diagnostics is a global leader in diagnostic testing, serving one in three adult Americans and half the physicians and hospitals in the United States. The company’s mission is to empower people to take action to improve health outcomes. Through its vast database of clinical lab results, Quest Diagnostics provides diagnostic insights that reveal new avenues for disease identification, treatment, and prevention.
Oxford Immunotec: A Global Leader in Immune-Regulated Condition Diagnostics
Oxford Immunotec is a global diagnostics company focused on developing and commercializing proprietary tests for immune-regulated conditions. The company’s T-SPOT.TB test has received regulatory approvals in over 50 countries, including the United States, Europe, Japan, and China.
A Transformative Acquisition for Infectious Disease Diagnostics
The acquisition of Oxford Immunotec‘s U.S. laboratory services business by Quest Diagnostics is a transformative event in the field of infectious disease diagnostics. It brings together two industry leaders with complementary strengths, creating a powerhouse in the development and delivery of innovative testing solutions. This acquisition will ultimately benefit healthcare providers and patients by expanding access to accurate and reliable tests, leading to improved diagnosis, treatment, and prevention of infectious diseases.
